You just read:

Helsinn Group And Eisai Announce FDA Acceptance Of New Drug Application For Investigational Compound Netupitant 300 mg + Palonosetron 0.50 mg (NEPA)

News provided by

Eisai Inc.

Dec 09, 2013, 10:00 ET